SULT1B1

Across TCGA pan-cancer cohorts, SULT1B1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SULT1B1 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SULT1B1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SULT1B1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SULT1B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.890	0.801	<.001	79	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	7	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	3	view →
HNSC	DFS	Median	All	0.894	1.000	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SULT1B1–PDAC (OS)

Open the PDAC breakdown →